Lupin Tops Global Pharma in S&P ESG Assessment 2025
Event summary
- Lupin scored 91/100 in S&P Global’s 2025 Corporate Sustainability Assessment, ranking No. 1 in pharma and across all sectors in India.
- This is the third consecutive year Lupin has been included in the Sustainability Yearbook 2026.
- The assessment evaluated over 9,200 companies across 59 industries, with only 848 making the Yearbook.
- Lupin’s recognition highlights its focus on responsible business practices, governance, environmental stewardship, and social impact.
The big picture
Lupin’s top ranking in the S&P ESG Assessment underscores the growing importance of sustainability in the pharmaceutical industry. As ESG criteria become critical for investor decisions and regulatory frameworks, Lupin’s leadership position may enhance its competitive edge, particularly in markets prioritizing responsible business practices. The recognition also reflects broader trends where pharma companies are increasingly measured by their environmental and social impact alongside financial performance.
What we're watching
- Sustainability Leadership
- How Lupin’s sustained ESG performance will influence investor preferences and regulatory compliance in the pharma sector.
- Competitive Differentiation
- Whether Lupin can translate its ESG leadership into market share gains against peers in key markets like the U.S. and India.
- Operational Integration
- The pace at which Lupin deepens ESG integration across its global value chain, including manufacturing and research operations.
Related topics